EU/3/19/2190 : Orphan designation for the treatment of hepatitis D virus infection
Peginterferon lambda-1a
Table of contents
Overview
On 21 August 2019, orphan designation EU/3/19/2190 was granted by the European Commission to Eiger Biopharmaceuticals Europe Limited, United Kingdom, for peginterferon lambda-1a for the treatment of hepatitis D virus infection.
The sponsorship was transferred to Eigerbio Europe Limited, Ireland, in October 2019.
Key facts
Active substance |
Peginterferon lambda-1a
|
Intended use |
Treatment of hepatitis D virus infection
|
Orphan designation status |
Positive
|
EU designation number |
EU/3/19/2190
|
Date of designation |
21/08/2019
|
Sponsor |
Eigerbio Europe Limited |
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: